Q2 Earnings Estimate for Lantheus Issued By Leerink Partnrs

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Lantheus in a note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz anticipates that the medical equipment provider will post earnings of $1.37 per share for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share.

LNTH has been the subject of several other research reports. Truist Financial restated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Price Performance

LNTH stock opened at $78.23 on Friday. Lantheus has a 1-year low of $56.44 and a 1-year high of $126.89. The business has a fifty day moving average price of $90.31 and a 200-day moving average price of $97.06. The stock has a market capitalization of $5.44 billion, a P/E ratio of 13.02 and a beta of 0.44.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. Janus Henderson Group PLC increased its position in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after buying an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC increased its position in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after buying an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after buying an additional 435,445 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Lantheus in the fourth quarter worth about $36,183,000. Finally, Groupama Asset Managment purchased a new stake in Lantheus in the third quarter worth about $439,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.